Related Experiment Videos
[Recent conception of collagen diseases]
1Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 17, 1999
Summary
Connective tissue diseases, including autoimmune and rheumatic disorders, are pathologically defined. While understanding has advanced, therapies lag, prompting development of novel, targeted pharmacological and biological agents.
Area of Science:
- Rheumatology
- Immunology
- Pathology
Context:
- Connective tissue diseases encompass a spectrum of disorders characterized by pathological features.
- These conditions are clinically classified as rheumatic disorders and pathogenically as autoimmune diseases.
- Includes original 'big 6' (SLE, RA, PSS, PN, PM/DM, RF) and other categorized disorders.
Purpose:
- To review the current understanding and therapeutic landscape of collagen and connective tissue diseases.
- To highlight the gap between mechanistic insights and clinical therapy.
- To introduce emerging therapeutic principles targeting immune processes.
Summary:
- Collagen diseases are defined by pathological features, classified clinically as rheumatic and pathogenically as autoimmune disorders.
- Despite significant progress in understanding disease mechanisms, therapeutic advancements have been limited.
- New knowledge is driving the development of novel pharmacological and biological agents for more specific immune interference.
Impact:
- Advances understanding of connective tissue disease classification and pathogenesis.
- Identifies a critical need for improved therapeutic strategies.
- Paves the way for more targeted and effective treatments for autoimmune and rheumatic conditions.